ArticleDermatology and therapy2021

Certolizumab Pegol for the Treatment of Moderate to Severe Plaque Psoriasis: 16-Week Results from a Phase 2/3 Japanese Study.

Yoshinori Umezawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.